George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Dechra Pharmaceuticals plc

12 Jan 2024 13:24

RNS Number : 5820Z
Barclays PLC
12 January 2024

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

Barclays PLC.

(b)

Owner or controller of interest and short

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DECHRA PHARMACEUTICALS PLC

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

offeror/offeree, state this and specify identity of

offeror/offeree:

(e)

Date position held/dealing undertaken:

11 Jan 2024

(f)

In addition to the company in 1(c) above, is the discloser making

NO

disclosures in respect of any other party to the offer?

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

to which the disclosure relates following the dealing(if any)

Class of relevant security:

1p ordinary

Interests

Short Positions

Number

(%)

Number

(%)

(1)

Relevant securities owned

and/or controlled:

6,853,899

6.02%

573,753

0.50%

(2)

Cash-settled derivatives:

and/or controlled:

572,699

0.50%

6,783,129

5.96%

(3)

Stock-settled derivatives (including options)

and agreements to purchase/sell:

0

0.00%

0

0.00%

TOTAL:

7,426,598

6.52%

7,356,882

6.46%

(b)

Rights to subscribe for new securities (including directors and other executive

options)

Class of relevant security in relation to

which subscription right exists

Details, including nature of the rights

concerned and relevant percentages:

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Class of relevant

Purchase/sale

Number of

Price per unit

security

securities

1p ordinary

Purchase

30,887

38.6238 GBP

1p ordinary

Purchase

24,112

38.6333 GBP

1p ordinary

Purchase

9,820

38.6277 GBP

1p ordinary

Purchase

4,774

38.6200 GBP

1p ordinary

Purchase

3,600

38.6427 GBP

1p ordinary

Purchase

2,282

38.6300 GBP

1p ordinary

Purchase

482

38.6400 GBP

1p ordinary

Sale

16,080

38.6200 GBP

1p ordinary

Sale

1,050

38.6219 GBP

1p ordinary

Sale

12

38.6194 GBP

(b)

Cash-settled derivative transactions

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

reference

unit

security

securities

1p ordinary

SWAP

Closing Long

3,600

38.6427 GBP

1p ordinary

SWAP

Decreasing Long

5,114

38.6200 GBP

1p ordinary

SWAP

Decreasing Long

6,544

38.6400 GBP

1p ordinary

SWAP

Decreasing Short

12

38.6194 GBP

1p ordinary

SWAP

Decreasing Short

16,080

38.6200 GBP

1p ordinary

CFD

Increasing Short

235

38.6200 GBP

1p ordinary

CFD

Increasing Short

4,834

38.6268 GBP

1p ordinary

SWAP

Increasing Short

5,601

38.6305 GBP

1p ordinary

SWAP

Increasing Short

7,007

38.6400 GBP

1p ordinary

CFD

Increasing Short

9,820

38.6277 GBP

1p ordinary

SWAP

Increasing Short

31,177

38.6238 GBP

(c)

Stock-settled derivative transactions (including options)

(i)

Writing, selling, purchasing or varying

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

date

money

relevant

selling,

securities

per unit

paid/

security

varying etc

to which

received

option

per unit

relates

(ii)

Exercising

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

securities

unit

(d)

Other dealings (including subscribing for new securities)

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

applicable)

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

to the offer or any person acting in concert with a party to the offer:

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

(c)

Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

12 Jan 2024

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RETEADFAFAALEFA
Date   Source Headline
16th Jan 20244:54 pmRNSHolding(s) in Company
16th Jan 20243:29 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20242:43 pmRNSHolding(s) in Company
16th Jan 20241:25 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:15 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20241:02 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
16th Jan 202412:50 pmRNSForm 8.5 (EPT/RI)-Replacement of Dechra
16th Jan 202412:44 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 202412:04 pmRNSHolding(s) in Company
16th Jan 202410:15 amRNSScheme of Arrangement becomes Effective
16th Jan 202410:11 amRNSForm 8.5 (EPT/NON-RI) - Dechra Pharmaceuticals PLC
16th Jan 202410:11 amRNSForm 8.5 (EPT/RI)
16th Jan 20249:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
16th Jan 20249:04 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
16th Jan 20249:00 amRNSHolding(s) in Company
16th Jan 20248:12 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
16th Jan 20247:39 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
16th Jan 20247:30 amRNSSuspension - Dechra Pharmaceuticals PLC
15th Jan 20244:51 pmRNSDirector/PDMR Shareholding
15th Jan 20243:51 pmRNSHolding(s) in Company
15th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20243:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:57 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20241:46 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
15th Jan 202412:35 pmGNWForm 8.3 - Dechra Pharmaceuticals PLC
15th Jan 202412:05 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:51 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 202411:25 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
15th Jan 20249:58 amRNSForm 8.5 (EPT/NON-RI)
15th Jan 20249:58 amRNSForm 8.5 (EPT/RI)
15th Jan 20249:31 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
15th Jan 20249:13 amRNSForm 8.3 - Dechra Pharmaceuticals plc
15th Jan 20247:29 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
12th Jan 20244:02 pmRNSCourt sanction of Scheme of Arrangement
12th Jan 20243:30 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20243:07 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:42 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20242:30 pmRNSHolding(s) in Company
12th Jan 20241:38 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
12th Jan 20241:24 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202412:03 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 202410:39 amGNWForm 8.3 - Dechra Pharmaceuticals PLC
12th Jan 202410:39 amRNSForm 8.5 (EPT/RI)
12th Jan 202410:36 amRNSForm 8.5 (EPT/NON-RI)
12th Jan 202410:35 amRNSForm 8.3 - Dechra Pharmaceuticals plc
12th Jan 20249:34 amRNSHolding(s) in Company
12th Jan 20249:22 amRNSForm 8.5 (EPT/RI)-Dechra Pharmaceuticals plc
12th Jan 20248:09 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.